Search alternatives:
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
ms decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 non » _ non (Expand Search), a non (Expand Search), e non (Expand Search)
5 ng » 5 mg (Expand Search), 5 g (Expand Search), 5 nm (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
ms decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 non » _ non (Expand Search), a non (Expand Search), e non (Expand Search)
5 ng » 5 mg (Expand Search), 5 g (Expand Search), 5 nm (Expand Search)
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
Juvenile demyelination leads to a substantial decrease in potassium currents in PV interneurons of the PFC.
Published 2025“…Scale: 500 pA, 100 ms. <b>B</b>. I–V curves showing a significant decrease in Kv amplitude in PV interneurons from mice that underwent juvenile demyelination. …”
-
54
-
55
-
56
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
Published 2025“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
-
57
-
58
-
59
-
60